Looking for driver pathways of acquired resistance to targeted therapy: Drug resistant subclone generation and sensitivity restoring by gene knock-down

Research output: Contribution to journalArticle

Abstract

The past two decades have seen a shift from cytotoxic drugs to targeted therapy in medical oncology. Although targeted therapeutic agents have shown more impressive clinical efficacy and minimized adverse effects than traditional treatments, drug resistance has become the main limitation to their benefits. Several preclinical in vitro/in vivo models of acquired resistance to targeted agents in clinical practice have been developed mainly by using two strategies: i) genetic manipulation for modeling genotypes of acquired resistance, and ii) in vitro/in vivo selection of resistant models. In the present work, we propose a unifying framework, for investigating the underlying mechanisms responsible for acquired resistance to targeted therapeutic agents, starting from the generation of drug-resistant cellular subclones to the description of silencing procedures used for restoring the sensitivity to the inhibitor. This simple time- and cost-effective approach is widely applicable, and could be easily extended to investigate resistance mechanisms to other targeted therapeutic drugs in different tumor histotypes.

Original languageEnglish
Article number56583
JournalJournal of Visualized Experiments
Volume2017
Issue number130
DOIs
Publication statusPublished - Dec 11 2017

Fingerprint

Gene Knockdown Techniques
Drug therapy
Genes
Drug Therapy
Pharmaceutical Preparations
Oncology
Tumors
Therapeutics
Medical Oncology
Drug Resistance
Genotype
Costs
Costs and Cost Analysis
Neoplasms

Keywords

  • Cancer biology
  • Clonogenic assay
  • Drug resistance
  • In vitro model
  • Issue 130
  • Re-sensitization
  • siRNA transfection
  • Targeted therapy

ASJC Scopus subject areas

  • Neuroscience(all)
  • Chemical Engineering(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

@article{2fa3eee8db904b0898452735186c5830,
title = "Looking for driver pathways of acquired resistance to targeted therapy: Drug resistant subclone generation and sensitivity restoring by gene knock-down",
abstract = "The past two decades have seen a shift from cytotoxic drugs to targeted therapy in medical oncology. Although targeted therapeutic agents have shown more impressive clinical efficacy and minimized adverse effects than traditional treatments, drug resistance has become the main limitation to their benefits. Several preclinical in vitro/in vivo models of acquired resistance to targeted agents in clinical practice have been developed mainly by using two strategies: i) genetic manipulation for modeling genotypes of acquired resistance, and ii) in vitro/in vivo selection of resistant models. In the present work, we propose a unifying framework, for investigating the underlying mechanisms responsible for acquired resistance to targeted therapeutic agents, starting from the generation of drug-resistant cellular subclones to the description of silencing procedures used for restoring the sensitivity to the inhibitor. This simple time- and cost-effective approach is widely applicable, and could be easily extended to investigate resistance mechanisms to other targeted therapeutic drugs in different tumor histotypes.",
keywords = "Cancer biology, Clonogenic assay, Drug resistance, In vitro model, Issue 130, Re-sensitization, siRNA transfection, Targeted therapy",
author = "Chiara Arienti and Sara Pignatta and Michele Zanoni and Michela Cortesi and Alice Zamagni and Filippo Piccinini and Anna Tesei",
year = "2017",
month = "12",
day = "11",
doi = "10.3791/56583",
language = "English",
volume = "2017",
journal = "Journal of Visualized Experiments",
issn = "1940-087X",
publisher = "Journal of Visualized Experiments",
number = "130",

}

TY - JOUR

T1 - Looking for driver pathways of acquired resistance to targeted therapy

T2 - Drug resistant subclone generation and sensitivity restoring by gene knock-down

AU - Arienti, Chiara

AU - Pignatta, Sara

AU - Zanoni, Michele

AU - Cortesi, Michela

AU - Zamagni, Alice

AU - Piccinini, Filippo

AU - Tesei, Anna

PY - 2017/12/11

Y1 - 2017/12/11

N2 - The past two decades have seen a shift from cytotoxic drugs to targeted therapy in medical oncology. Although targeted therapeutic agents have shown more impressive clinical efficacy and minimized adverse effects than traditional treatments, drug resistance has become the main limitation to their benefits. Several preclinical in vitro/in vivo models of acquired resistance to targeted agents in clinical practice have been developed mainly by using two strategies: i) genetic manipulation for modeling genotypes of acquired resistance, and ii) in vitro/in vivo selection of resistant models. In the present work, we propose a unifying framework, for investigating the underlying mechanisms responsible for acquired resistance to targeted therapeutic agents, starting from the generation of drug-resistant cellular subclones to the description of silencing procedures used for restoring the sensitivity to the inhibitor. This simple time- and cost-effective approach is widely applicable, and could be easily extended to investigate resistance mechanisms to other targeted therapeutic drugs in different tumor histotypes.

AB - The past two decades have seen a shift from cytotoxic drugs to targeted therapy in medical oncology. Although targeted therapeutic agents have shown more impressive clinical efficacy and minimized adverse effects than traditional treatments, drug resistance has become the main limitation to their benefits. Several preclinical in vitro/in vivo models of acquired resistance to targeted agents in clinical practice have been developed mainly by using two strategies: i) genetic manipulation for modeling genotypes of acquired resistance, and ii) in vitro/in vivo selection of resistant models. In the present work, we propose a unifying framework, for investigating the underlying mechanisms responsible for acquired resistance to targeted therapeutic agents, starting from the generation of drug-resistant cellular subclones to the description of silencing procedures used for restoring the sensitivity to the inhibitor. This simple time- and cost-effective approach is widely applicable, and could be easily extended to investigate resistance mechanisms to other targeted therapeutic drugs in different tumor histotypes.

KW - Cancer biology

KW - Clonogenic assay

KW - Drug resistance

KW - In vitro model

KW - Issue 130

KW - Re-sensitization

KW - siRNA transfection

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85037712306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037712306&partnerID=8YFLogxK

U2 - 10.3791/56583

DO - 10.3791/56583

M3 - Article

AN - SCOPUS:85037712306

VL - 2017

JO - Journal of Visualized Experiments

JF - Journal of Visualized Experiments

SN - 1940-087X

IS - 130

M1 - 56583

ER -